A phase II trial of an experimental respiratory syncytial virus (RSV) vaccine created by Novavax Inc. prevented symptoms of the common and sometimes deadly virus in as many as 46 percent of older adults, giving the company a strong foundation ahead of a planned pivotal phase III trial that could start as early as the fourth quarter and boding well for another program testing the vaccine to protect infants via maternal immunization scheduled to report data in September.